Improved drug delivery to brain metastases by peptide-mediated permeabilization of the blood-brain barrier.

  • Translational Radiomics
  • NORLUX Neuro-Oncology Laboratory
November 01, 2019 By:
  • Aasen SN
  • Espedal H
  • Holte CF
  • Keunen O
  • Karlsen TV
  • Tenstad O
  • Maherally Z
  • Miletic H
  • Hoang T
  • Eikeland AV
  • Baghirov H
  • Olberg DE
  • Pilkington GJ
  • Sarkar G
  • Jenkins RB
  • Sundstrom T
  • Bjerkvig R
  • Thorsen F.

Patients with melanoma have a high risk of developing brain metastasis, which is associated with a dismal prognosis. During early stages of metastasis development, the blood-brain barrier (BBB) is likely intact, which inhibits sufficient drug delivery into the metastatic lesions. We investigated the ability of the peptide, K16ApoE, to permeabilize the BBB for improved treatment with targeted therapies preclinically. Dynamic contrast enhanced MRI (DCE-MRI) was carried out on NOD/SCID mice to study the therapeutic window of peptide-mediated BBB permeabilization. Further, both in vivo and in vitro assays were used to determine K16ApoE toxicity and to obtain mechanistic insight into its action on the BBB. The therapeutic impact of K16ApoE on metastases was evaluated combined with the mitogen-activated protein kinase pathway inhibitor dabrafenib, targeting BRAF mutated melanoma cells, which is otherwise known not to cross the intact BBB. Our results from the DCE-MRI experiments showed effective K16ApoE-mediated BBB permeabilization lasting for up to 1 hour. Mechanistic studies showed a dose-dependent effect of K16ApoE caused by induction of endocytosis. At concentrations above IC50, the peptide additionally showed nonspecific disturbances on plasma membranes. Combined treatment with K16ApoE and dabrafenib reduced the brain metastatic burden in mice and increased animal survival, and PET/CT showed that the peptide also facilitated the delivery of compounds with molecular weights as large as 150 kDa into the brain. To conclude, we demonstrate a transient permeabilization of the BBB, caused by K16ApoE, that facilitates enhanced drug delivery into the brain. This improves the efficacy of drugs that otherwise do not cross the intact BBB.

2019 Nov. Mol Cancer Ther.18(11):2171-2181. Epub 2019 Aug 29.
Other information